Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Loratadine (formerly SCH29851; SCH-29851; Claritin; Loratidine; Clarityn; Alavert) is a potent and 2nd-generation histamine H1 receptor antagonist which has been approved for the treatment of allergies such as allergic rhinitis and urticaria. It also functions as a selective inhibitor of B(0)AT2 with IC50 of 4 μM. Loratadine doesn't have any effects that depress the central nervous system, like sleepiness. It has been demonstrated to suppress histamine and leukotriene C4 release from rodent mast cells as well as to suppress allergic bronchospasm in guinea pigs. Loratadine is an inverse peripheral histamine H1-receptor agonist that is selective.
Targets |
H1 receptor; B(0)AT2 ( IC50 = 4 μM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C22H23CLN2O2
|
|
---|---|---|
Molecular Weight |
382.88
|
|
Exact Mass |
382.14
|
|
Elemental Analysis |
C, 69.01; H, 6.05; Cl, 9.26; N, 7.32; O, 8.36
|
|
CAS # |
79794-75-5
|
|
Related CAS # |
Loratadine-d4; 381727-27-1; Loratadine-d5; 1398065-63-8
|
|
Appearance |
Solid powder
|
|
SMILES |
CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
|
|
InChi Key |
JCCNYMKQOSZNPW-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
|
|
Chemical Name |
ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO + Corn oil: 4.0mg/ml (10.45mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6118 mL | 13.0589 mL | 26.1178 mL | |
5 mM | 0.5224 mL | 2.6118 mL | 5.2236 mL | |
10 mM | 0.2612 mL | 1.3059 mL | 2.6118 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05421416 | Not yet recruiting | Drug: Loratadine Drug: Placebo |
Stem Cell Transplant Complications |
AHS Cancer Control Alberta | November 1, 2023 | Phase 2 |
NCT05243706 | Not yet recruiting | Drug: Loratadine Drug: Diosmin/ Hesperidin |
Vinca Alkaloid Adverse Reaction |
Ain Shams University | March 1, 2022 | Phase 3 |
NCT04211259 | Recruiting | Drug: Loratadine Other: Placebo |
Plasma Cell Myeloma | Rutgers, The State University of New Jersey |
April 18, 2022 | Early Phase 1 |
NCT06217367 | Recruiting | Drug: 10 mg Loratadine Drug: 5 mg Desloratadine |
Heat Illness Allergic Rhinitis Heat Injury |
Lakehead University | December 5, 2023 | Phase 4 |
NCT02513290 | Completed | Drug: Bilastine Drug: Loratadine |
Allergic Rhinitis | Universidade do Sul de Santa Catarina |
August 2013 | Phase 4 |
Effects of loratadine on hKv1.5 channels expressed in a mouse L-cell. Cardiovasc Res . 1997 Aug;35(2):341-50. td> |
Concentration dependence of loratadine-induced block of hKv1.5. Cardiovasc Res . 1997 Aug;35(2):341-50. td> |
Effect of 1 μM loratadine on the steady-state current–voltage (I–V) relationships (500 ms isochronal). Cardiovasc Res . 1997 Aug;35(2):341-50. td> |